IGC Pharma's novel approach to
Alzheimer's Disease
Reach out to learn more about IGC-AD1's Phase 2b trial for agitation in dementia due to Alzheimer's
Alzheimer's disease affects over 55 million individuals worldwide 1
In treating agitation, which affects 40-80% of individuals with Alzheimer’s disease2, IGC-AD1 has shown promising results.
Drag to discover more
Impacting Lives: Our Work Matters
With no known cure for Alzheimer’s disease, our drugs have the potential to change lives.
5th Leading
Cause of death among
Americans aged 65+3
Expected cost of Alzheimer’s and dementia by 2050 (in 2024 dollars) if no treatment or cure is found3
From the CEO's desk:
Vertical integration
Periodic updates and perspectives on various aspects of our business.
Science Spotlight
Welcome to “Science Spotlight” – your exclusive platform for insights into neurological disorders. Dr. Juan Manuel Orjuela and the IGC Pharma scientific team bring you in-depth articles on conditions such as Alzheimer’s disease, offering comprehensive updates on treatment and understanding their impact on individuals and families. Explore the roles of caregivers and dynamics within affected families. Stay informed with our latest article.
- Feature Article
Psychosis in Parkinson
Parkinson's awareness month
Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common symptoms involve visual or auditory hallucinations, distorted perception, and experiences. More challenging symptoms may occur in the form of delusions, which often cause agitation, aggressiveness, and affect the quality of life of the patient and their families.
Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively. The results indicate that IGC-AD1 clinically reduced agitation compared to placebo.
Parkinson's awareness month ____________________________ Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common symptoms involve visual or auditory hallucinations, distorted perception, and experiences. More challenging symptoms may occur in the form of delusions, which often cause agitation, aggressiveness, and affect the quality of life of the patient and their families.
By: Faith Ashmore Benzinga …
By: Faith Ashmore …
Synesthesia is a complex experience that involves perceiving the elements of the world with more than one sense. By integrating the knowledge of neuroscience with these aspects of perception, scientists have been able to map synchronous patterns of activation in brain regions that do not entirely relate to the stimulus nature. The intriguing nature of this process invites people to be more aware of what they can perceive in a world saturated with external information.
In Alzheimer's disease research, the integration of artificial intelligence (AI) enables researchers to uncover patterns and biomarkers faster, facilitating earlier diagnosis and personalized therapies. Embracing these new technologies not only enhances the understanding of AD but also propels the development of innovative treatments for this complex neurological condition.
Latest News
Investing in the Future: Building Brighter Lives for Children
At IGC Pharma, we recognize our commitment to patients, caregivers, and their families, including children. Explore our programs dedicated to children.
- World Health Organization, Dementia, Key facts, 15 March 2023.
- Van der Mussele S et al. Agitation-associated behavioral symptoms in MCI and Alzheimer’s dementia. Aging Ment Health 2014;19(3):247–57.
- Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5)